In combination with CALRmut-specific therapeutic cancer vaccination, these anti-regulatory vaccines have the potential to induce a clinical response, especially as patients with MPN harbor T cells specific to both PD-L1- and ARG-1-derived epitopes (58, 59). This evidence concerns the gene ARG1 and cancer.